Souhaitez-vous accéder aux communiqués récents ?

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day...

ROH, a financial infrastructure platform for hospitality, was named “TravelTech AI Platform of the Year” by TravelTech Breakthrough.

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following...

LONDON, May 06, 2026 (GLOBE NEWSWIRE) -- First Quarter Financial Highlights. On May 6, 2026, pursuant to the Company's capital return policy (the "Capital Return Policy"), the Board of Directors...

PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs...

Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15...

Net sales of $7.4 billion, an increase of 10.7%Net income of $239 million, a decrease of 25.8%Adjusted EBITDA1 of $776 million, a decrease of 10.6%Raising full year 2026 Organic Sales2 guidance range...

GROWTH IN THREE OF FOUR DIVISIONS & IMPROVEMENTS IN MULTIPLE KEY FINANCIAL METRICS FIRST QUARTER NET INCOME OF $7.3 MILLION, UP $4.4 MILLION YEAR-OVER-YEAR FIRST QUARTER ADJUSTED EBITDA MARGIN...

DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated...

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients...